Company profile: SynDevRx
1.1 - Company Overview
Company description
- Provider of polymer-based drug conjugates for oncology, including evexomostat (SDX-7320), a polymer-drug conjugate that releases a fumagillol derivative in vivo to target cancer and systemic metabolic hormone dysfunction. Sponsors clinical trials across various cancer types, provides an expanded access program, and advances a pipeline focused on cancers sensitive to metabolic hormones, leveraging metabo-oncology and polymer-drug conjugation to improve safety and activity.
Products and services
- Evexomostat (SDX-7320): A polymer-based polymer-drug conjugate that releases a small-molecule fumagillol derivative in vivo, targeting cancer and systemic metabolic hormone dysfunction for dual oncology-metabolic impact
- Polymer-Drug Conjugation: A method-based approach attaching small molecules to polymers to improve drug safety and activity, used to architect evexomostat (SDX-7320) for in vivo release
- Clinical Trials: Sponsor-led clinical studies evaluating evexomostat (SDX-7320) safety and efficacy in various cancer types, aligning with its targeting of cancer and systemic metabolic hormone dysfunction
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to SynDevRx
Algernon Pharmaceuticals
HQ: Canada
Website
- Description: Provider of pharmaceutical R&D, in-licensing, and commercialization, advancing NP-120 (Ifenprodil) investigated for chronic cough and idiopathic pulmonary fibrosis, NP-251 (Repirinast) repurposed for chronic kidney disease, and AP-188 (DMT), a naturally occurring psychedelic compound explored for stroke and traumatic brain injury.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Algernon Pharmaceuticals company profile →
Apotheca Biosciences
HQ: United States
Website
- Description: Provider of cutting-edge medical products, nutraceuticals, and formulation and delivery technologies for the healthcare and consumer care industry, including transdermal, sublingual, and nasal delivery technologies for precise, controlled dosing of cannabinoids.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Apotheca Biosciences company profile →
Chiva Pharmaceuticals
HQ: United States
Website
- Description: Provider of global pharmaceutical solutions focused on bringing the best standard of care to the Chinese market and making drugs developed in China available worldwide.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Chiva Pharmaceuticals company profile →
Cyclo Therapeutics
HQ: United States
Website
- Description: Provider of cyclodextrin-based therapeutics, including Trappsol® Cyclo™, a proprietary hydroxypropyl beta cyclodextrin formulation in clinical trials for Niemann-Pick Disease Type C1 and in a Phase 2b trial for early Alzheimer’s disease, leveraging data from an Expanded Access program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cyclo Therapeutics company profile →
PanGenetics
HQ: The Netherlands
Website
- Description: Provider of clinical development services for monoclonal antibodies targeting immune-mediated diseases, specializing in advancing candidates from late research stage through clinical proof of concept; based in Utrecht, the Netherlands, with an office in Cambridge, UK.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PanGenetics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for SynDevRx
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to SynDevRx
2.2 - Growth funds investing in similar companies to SynDevRx
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for SynDevRx
4.2 - Public trading comparable groups for SynDevRx
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →